John Wang

General Manager

Iovaxis Therapeutics

John Wang

Dr. Wang graduated from Chinese Pharmaceutical University, and received his PhD from “Mario Negri Institute for Pharmacological Research” at Milan, Italy, and postdoc training at University of Arizona, Tucson, USA.

Dr. Wang joined the Department of Molecular Immunology of Commonwealth Serum Laboratory (CSL) at Melbourn, Australia in 1988 and then its spin-off company "Mimotopes" as the head of Biology. Dr. Wang was transferred to Chiron Corp in 1995 after Mimotopes was acquired by Chiron and then joined Novartis in 2006 when Chiron was acquired by Novartis. Dr. John Wang served as an Associate Director and Senior Research Investigator at Novartis. Dr. Wang has over fifty publications, monographs and international patents.

While working in the US, Dr. Wang joined the Society for Biomolecular Screening (SBA) and was elected to the Board of SBS (later became SLAS) and the President-elect from 2004-2010. Dr. Wang also co-founded the Chinese America Biopharmaceutical Society (CABS) at San Francisco area and served as the Editor-in-Chief of the society journal《Trends in BioPharmaceutical Industry》between 2005-2010

Dr, John Wang returned to China on 2010 and co-funded ImmuOn Therapeutics and later a sister company IOVaxis Therapeutics. The two companies are committed to develop epitope-based preventive and therapeutic vaccines against cancer and viruses. IOVaxis currently has two neoantigen-based cancer vaccine IND applications waiting to be approved by NMPA. Since the eruption of COVID-19, ImmuOn has also been actively researching and developing a neutralizing epitope based vaccine to join the global fighting to the pandemic.